US 12,006,364 B2
Anti-CD100 antibodies and methods for using the same
Ernest S. Smith, West Henrietta, NY (US); and Terrence Lee Fisher, Rochester, NY (US)
Assigned to VACCINEX, INC., Rochester, NY (US)
Filed by Vaccinex, Inc., Rochester, NY (US)
Filed on Jan. 31, 2022, as Appl. No. 17/588,427.
Application 15/581,573 is a division of application No. 13/800,713, filed on Mar. 13, 2013, granted, now 9,676,840, issued on Jun. 13, 2017.
Application 17/588,427 is a continuation of application No. 15/581,573, filed on Apr. 28, 2017, granted, now 11,274,149.
Application 13/800,713 is a continuation of application No. 12/776,187, filed on May 7, 2010, granted, now 8,496,938, issued on Jul. 30, 2013.
Claims priority of provisional application 61/325,213, filed on Apr. 16, 2010.
Claims priority of provisional application 61/176,826, filed on May 8, 2009.
Prior Publication US 2022/0185884 A1, Jun. 16, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/00 (2006.01); A61K 38/17 (2006.01); A61K 39/395 (2006.01); A61K 45/06 (2006.01); A61P 25/00 (2006.01); C07K 16/18 (2006.01); C07K 16/28 (2006.01); C07K 16/30 (2006.01)
CPC C07K 16/2803 (2013.01) [A61K 38/1774 (2013.01); A61K 39/0001 (2013.01); A61K 39/3955 (2013.01); A61K 39/39558 (2013.01); A61K 39/4611 (2023.05); A61K 39/46433 (2023.05); A61K 45/06 (2013.01); A61P 25/00 (2018.01); C07K 16/18 (2013.01); C07K 16/2896 (2013.01); C07K 16/30 (2013.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/73 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); C07K 2317/94 (2013.01)] 13 Claims
 
1. A method of neutralizing CD100 in an animal, comprising administering to the animal a composition comprising:
a) an isolated antibody or antigen-binding fragment thereof that specifically binds to a semaphorin 4D (SEMA4D) receptor; and
b) a pharmaceutically acceptable carrier,
wherein the antibody or antigen-binding fragment thereof comprises a heavy chain variable region (VH) polypeptide comprising VH complementarity determining regions (CDR) VH-CDR1, VH-CDR2, and VH-CDR3 amino acid sequences comprising SEQ ID Nos: 6, 7, and 8, respectively, and a light chain variable region (VL) polypeptide comprising VL complementarity determining regions VL-CDR1, VL-CDR2, and VL-CDR3 amino acid sequences comprising SEQ ID Nos: 14, 15, and 16, respectively.